{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:42Z","timestamp":1774343082295,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>We aimed to analyse serious cardiac adverse drug reactions to COVID-19 vaccines from the Europe-wide EudraVigilance database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In this retrospective, cross-sectional study, the EudraVigilance database was searched to identify suspected serious cardiac post-vaccination adverse drug reactions to COVID-19 vaccines. This data was coupled with the number of total vaccine doses administered in the European Economic Area for Comirnaty (Pfizer BioNTech), Spikevax (Moderna), Vaxzevria (AstraZeneca), Jcovden (Janssen), Nuvaxovid (Novavax), products, available from the European Centre for Disease Prevention and Control \u2018Vaccine Tracker\u2019 database. The analysis included 772\u2009228\u2009309 administered doses of eligible vaccines from the \u2018Vaccine Tracker\u2019 database and 86\u2009051 eligible records of cardiac adverse drug reactions from the EudraVigilance database. The frequency of most of the investigated adverse drug reactions was very rare (&amp;lt;1\/10\u2009000 i.e. &amp;lt;100\/1\u2009000\u2009000 doses). The lowest risk of any serious cardiac adverse drug reactions was noticed for vaccination with Comirnaty (135.5 per million doses), while Spikevax, Jcovden, Vaxzevria, and Nuvaxovid were characterized by higher risk (respectively, 140.9, 194.8, 313.6, and 1065.2 per million doses). The most common complications of vaccinations included syncope, arrhythmia, tachycardia, palpitations, angina pectoris, hypertension, myocarditis, thrombosis, and pulmonary embolism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The risk of serious cardiac adverse drug reactions to COVID-19 vaccines is low and the benefit of active immunization against that disease seems to outweigh the potential risk of serious post-vaccination cardiac adverse drug reactions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae063","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:30:55Z","timestamp":1724387455000},"page":"599-607","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-0800","authenticated-orcid":false,"given":"Wojciech","family":"Nazar","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Medical University of Gda\u0144sk , Marii Sk\u0142odowskiej-Curie 3a, 80-210 Gda\u0144sk ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-0957","authenticated-orcid":false,"given":"Jan","family":"Romantowski","sequence":"additional","affiliation":[{"name":"Department of Allergology, Faculty of Medicine, Medical University of Gda\u0144sk , Smoluchowskiego 17, 80-214 Gda\u0144sk ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1089-1911","authenticated-orcid":false,"given":"Marek","family":"Niedoszytko","sequence":"additional","affiliation":[{"name":"Department of Allergology, Faculty of Medicine, Medical University of Gda\u0144sk , Smoluchowskiego 17, 80-214 Gda\u0144sk ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2269-1880","authenticated-orcid":false,"given":"Ludmi\u0142a","family":"Dani\u0142owicz-Szymanowicz","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gda\u0144sk , Smoluchowskiego 17, 80-214 Gda\u0144sk ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2024110701231870600_bib1","first-page":"6588","article-title":"Safety of COVID-19 vaccines","volume-title":"J Med Virol","author":"Al Khames Aga","year":"2021"},{"key":"2024110701231870600_bib2","doi-asserted-by":"crossref","first-page":"2096970","DOI":"10.1080\/21645515.2022.2096970","article-title":"CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2","volume":"18","author":"Jin","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2024110701231870600_bib3","article-title":"Safety of COVID-19 vaccines | EMA"},{"key":"2024110701231870600_bib4","article-title":"COVID-19 medicines | EMA"},{"key":"2024110701231870600_bib5","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2024110701231870600_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/ehjqcco\/qcab090","article-title":"Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines","volume":"8","author":"Foltran","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2024110701231870600_bib7","article-title":"Adverse drug reaction | EMA"},{"key":"2024110701231870600_bib8","article-title":"EudraVigilance | EMA"},{"key":"2024110701231870600_bib9","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1002\/iid3.807","article-title":"Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia","volume":"11","author":"Yasmin","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"2024110701231870600_bib10","doi-asserted-by":"crossref","first-page":"729251","DOI":"10.3389\/fimmu.2021.729251","article-title":"COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis","volume":"12","author":"Bilotta","year":"2021","journal-title":"Front Immunol"},{"key":"2024110701231870600_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.122.059970","article-title":"Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex","volume":"146","author":"Patone","year":"2022","journal-title":"Circulation"},{"key":"2024110701231870600_bib12","doi-asserted-by":"crossref","first-page":"1123385","DOI":"10.3389\/fcvm.2023.1123385","article-title":"Acute myocardial infarction after inactivated COVID-19 vaccination: a case report and literature review","volume":"10","author":"Ou","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2024110701231870600_bib13","first-page":"120","article-title":"ST-segment elevation acute myocardial infarction associated to Covid-19 vaccination in A healthy young adult with normal coronary arteries","volume":"49","author":"Pintos-Belotto","year":"2023","journal-title":"Curr Health Sci J"},{"key":"2024110701231870600_bib14","doi-asserted-by":"crossref","first-page":"E37196","DOI":"10.1097\/MD.0000000000037196","article-title":"Fatal arrythmia in a young man after COVID-19 vaccination: an  autopsy report","volume":"103","author":"Minato","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2024110701231870600_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amjcard.2024.02.015","article-title":"Fatal acute myocardial infarction with normal epicardial coronary arteries shortly following COVID-19 vaccination","volume":"218","author":"Roberts","year":"2024","journal-title":"Am J Cardiol"},{"key":"2024110701231870600_bib16","author":"Vaxzevria"},{"key":"2024110701231870600_bib17","author":"Jcovden"},{"key":"2024110701231870600_bib18","author":"Spikevax"},{"key":"2024110701231870600_bib19"},{"key":"2024110701231870600_bib20"},{"key":"2024110701231870600_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024110701231870600_bib22"},{"key":"2024110701231870600_bib23","article-title":"COVID-19 Vaccine Tracker | European Centre for Disease Prevention and Control"},{"key":"2024110701231870600_bib24","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jcmg.2020.07.015","article-title":"Proposed requirements for cardiovascular imaging-related machine learning evaluation (PRIME)","volume":"13","author":"Sengupta","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024110701231870600_bib25","article-title":"EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome | EMA"},{"key":"2024110701231870600_bib26","doi-asserted-by":"crossref","first-page":"101077","DOI":"10.1016\/j.cpcardiol.2021.101077","article-title":"Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk?","volume":"47","author":"Hana","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2024110701231870600_bib27","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.2147\/IJGM.S324349","article-title":"Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database","volume":"14","author":"Kaur","year":"2021","journal-title":"Int J Gen Med"},{"key":"2024110701231870600_bib28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/vaccines10050700","article-title":"Cardiac adverse events after vaccination\u2014a systematic review","volume":"10","author":"Parmar","year":"2022","journal-title":"Vaccines"},{"key":"2024110701231870600_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hrtlng.2023.02.003","article-title":"Cardiovascular complications of COVID-19 vaccines: a review of case-report and case-series studies","volume":"59","author":"Paknahad","year":"2023","journal-title":"Heart Lung"},{"key":"2024110701231870600_bib30","first-page":"e15576","article-title":"Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines","volume":"13","author":"Vidula","year":"2021","journal-title":"Cureus"},{"key":"2024110701231870600_bib31","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.3346\/jkms.2022.37.e73","article-title":"Clinical features of patients presenting to the emergency department with cardiovascular adverse reactions after COVID-19 mRNA vaccination","volume":"37","author":"Oh","year":"2022","journal-title":"J Korean Med Sci"},{"key":"2024110701231870600_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/00325481.2022.2161249","article-title":"Current evidence of COVID-19 vaccination-related cardiovascular events","volume":"135","author":"Khiali","year":"2023","journal-title":"Postgrad Med"},{"key":"2024110701231870600_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin. Med"},{"key":"2024110701231870600_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0019-5154.182410","article-title":"Methodology series Module 3: cross-sectional studies","volume":"61","author":"Setia","year":"2016","journal-title":"Indian J Dermatol"},{"key":"2024110701231870600_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"2024110701231870600_bib36","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.3390\/ijerph19084584","article-title":"A social network analysis of Twitter data related to blood clots and vaccines","volume":"19","author":"Ahmed","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2024110701231870600_bib37","doi-asserted-by":"crossref","first-page":"e2023054","DOI":"10.4178\/epih.e2023054","article-title":"Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events","volume":"45","author":"Noh","year":"2023","journal-title":"Epidemiol Health"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae063\/59239037\/pvae063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/7\/599\/60456911\/pvae063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/7\/599\/60456911\/pvae063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T01:23:48Z","timestamp":1730942628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/7\/599\/7739170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae063","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,8,22]]}}}